BioCentury
ARTICLE | Clinical News

EntreMed reports Panzem data

January 29, 2008 1:02 AM UTC

EntreMed (NASDAQ:ENMD) said interim data in 29 evaluable patients who received Panzem NCD 2-methoxyestradiol plus Avastin bevacizumab showed that 27 patients (87%) had stable disease and two (7%) had progressive disease as their best response. The open-label, Phase II trial is evaluating the combination to treat advanced or metastatic carcinoid tumors. Median follow-up was more than eight months; 14 patients have been treated for at least six months, and, of these, nine have been treated for more than a year. Median progression-free survival and overall survival have not been reached. Data were presented at the Gastrointestinal Cancers Symposium in Orlando. ...